Seminar Friday the 2nd of December 11.30 am
13 February 2014
The next CRCL/CLB seminar will take place Friday the 2nd of December, 11.30am in the Multimedias meeting room (Centre Léon Bérard, 2nd floor) We are pleased to welcome Gabriel ICHIM (CRCL/LabEx DevWeCan). His talk will focus on: “Exploring the oncogenic role of apoptosis”.
2e conference “Stem Cells and Cancer”
13 September 2016
The 2e conference “Stem Cells and Cancer” wwill take place Novembre 15-16, 2016. This event is aimed at bringing together world experts in the fields of embryonic, adult and cancer stem cells. The synergy created by the reunion of leaders at the crossroad of those research themes will highlight novel approaches to address the important challenges associated with stem cells biology and therapeutics.
Information and registration: http://scac.ada.wats-on.co.uk/
ZEB1-mediated melanoma cell plasticity enhances resistance to MAPK inhibitors
29 November 2016
This work involved the team of Alain Puisieux.
Targeted therapies with MAPK inhibitors (MAPKi) are faced with severe problems of resistance in BRAF-mutant melanoma. In parallel to the acquisition of genetic mutations, melanoma cells may also adapt to the drugs through phenotype switching. The ZEB1 transcription factor, a known inducer of EMT and invasiveness, is now considered as a genuine oncogenic factor required for tumor initiation, cancer cell plasticity, and drug resistance in carcinomas. Here, we show that high levels of ZEB1 expression are associated with inherent resistance to MAPKi in BRAFV600-mutated cell lines and tumors.
PubMed access: click here
Structural Decoding of the Netrin-1/UNC5 Interaction and its Therapeutical Implications in Cancers
25 March 2016
This study involves the team of Patrick Mehlen.
Netrin-1 has been shown to be up-regulated in a fraction of human cancers as a mechanism to allow these tumors to escape the pro-apoptotic activity of some of its main dependence receptors, the UNC5 homologs (UNC5H). Here we identify the V-2 domain of netrin-1 to be important for its interaction with the Ig1/Ig2 domains of UNC5H2. We generate a humanized anti-netrin-1 antibody that disrupts the interaction between netrin-1 and UNC5H2 and triggers death of netrin-1-expressing tumor cells in vitro. We also present evidence that combining the anti-netrin-1 antibody with epidrugs such as decitabine could be effective in treating tumors showing no or modest netrin-1 expression. These results support that this antibody is a promising drug candidate.
PubMed access: click here